TY - JOUR
T1 - Using a low-dose contraceptive in women 35 years of age and over
T2 - 20 μg estradiol/100 μg levonorgestrel
AU - Carr, Bruce R.
AU - DelConte, Anthony
N1 - Funding Information:
This study was funded by Wyeth-Ayerst Laboratories, St. Davids, PA, USA.
Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2002
Y1 - 2002
N2 - The efficacy, safety, and cycle control of a low-dose oral contraceptive (OC) containing 20 μg ethinyl estradiol (EE) and 100 μg levonorgestrel (LNG) has been demonstrated in a large trial with 1708 women (≥15 years old with regular menstrual cycles). The objective of this study was to analyze the same parameters in 218 of the 1708 women who were 35 years of age and older. Women were administered the 28-day, combination OC (20 μg EE/100 μg LNG; 21 days active medication/7 days placebo) for up to 3 years. During 3859 cycles evaluated for efficacy, one pregnancy occurred (Pearl index 0.34). The most common adverse events cited as reasons for discontinuation were hypertension (3% of subjects), headache (2%), and metrorrhagia (2%). One subject withdrew as a result of a serious adverse event. Breakthrough bleeding, spotting, and bleeding and spotting occurred in 2.9%, 11.0%, and 6.8%, respectively, of the 3739 cycles evaluated for cycle control. This low-dose, monophasic regimen of 20 μg EE/100 μg LNG is an effective, safe, and tolerable contraceptive and provides good cycle control for women 35 years of age and older.
AB - The efficacy, safety, and cycle control of a low-dose oral contraceptive (OC) containing 20 μg ethinyl estradiol (EE) and 100 μg levonorgestrel (LNG) has been demonstrated in a large trial with 1708 women (≥15 years old with regular menstrual cycles). The objective of this study was to analyze the same parameters in 218 of the 1708 women who were 35 years of age and older. Women were administered the 28-day, combination OC (20 μg EE/100 μg LNG; 21 days active medication/7 days placebo) for up to 3 years. During 3859 cycles evaluated for efficacy, one pregnancy occurred (Pearl index 0.34). The most common adverse events cited as reasons for discontinuation were hypertension (3% of subjects), headache (2%), and metrorrhagia (2%). One subject withdrew as a result of a serious adverse event. Breakthrough bleeding, spotting, and bleeding and spotting occurred in 2.9%, 11.0%, and 6.8%, respectively, of the 3739 cycles evaluated for cycle control. This low-dose, monophasic regimen of 20 μg EE/100 μg LNG is an effective, safe, and tolerable contraceptive and provides good cycle control for women 35 years of age and older.
KW - Ethinyl estradiol
KW - Levonorgestrel
KW - Low-dose oral contraceptive
KW - Perimenopause
UR - http://www.scopus.com/inward/record.url?scp=0036597741&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036597741&partnerID=8YFLogxK
U2 - 10.1016/S0010-7824(02)00292-5
DO - 10.1016/S0010-7824(02)00292-5
M3 - Article
C2 - 12127636
AN - SCOPUS:0036597741
SN - 0010-7824
VL - 65
SP - 397
EP - 402
JO - Contraception
JF - Contraception
IS - 6
ER -